As of November 10, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of TELA Bio, Inc. The largest reported stake is Ew Healthcare Partners Fund 2, L.P.'s, at 17.23%. 9 filings are on record since August 14, 2025 (Schedule 13D, June 9, 2026).
Sell to companies like TELA Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Nantahala Capital Management, LLC · Sole voting: 0 · Shared voting: 5,794,114 · Sole dispositive: 0 · Shared dispositive: 5,794,114 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: SilverArc Capital Management, LLC · Sole voting: 0 · Shared voting: 2,137,201 · Sole dispositive: 0 · Shared dispositive: 2,137,201 · SCHEDULE 13G/A, 2026-08-14
- · Holder: SilverArc Capital Management, LLC · Percent: 4.8% · SCHEDULE 13G
- · Holder: Ew Healthcare Partners Fund 2, L.P. · Percent: 17.23% · Shares: 3,031,617 · SCHEDULE 13D
- · Holder: Lytton, Laurence W. · Percent: 5.5% · SCHEDULE 13G/A
TELA Bio, Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: about 201 jobs, latest 2026-08-31 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Ew Healthcare Partners Fund 2, L.P. | 17.23% | 3,031,617 | SCHEDULE 13D, 2026-06-09 | 2026-06-09 |
| Nantahala Capital Management, LLC | 12.94% | 5,794,114 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Lytton, Laurence W. | 5.5% | 2,442,341 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| SilverArc Capital Management, LLC | 4.8% | 2,137,201 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Grow Funds, LLC. | SCHEDULE 13G/A, 2025-10-15 | 2025-09-30 |
Holding shares or following this stake? See who's behind TELA Bio, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on TELA Bio, Inc. and the records around it.
TELA Bio, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Layoff notices Aug 2026
- Who owns it
Companies that share a holder
- GROW FUNDS, LLC. also filed stake reports on 2 other companies: BranchOut Food Inc. (Oct 2026), BUDA JUICE, INC. (Mar 2026)
- SilverArc Capital Management, LLC also filed stake reports on 8 other companies: Cellectar Biosciences Inc (Aug 2026), ELUTIA INC. (Aug 2026), Fractyl Health Inc (May 2026)
- Lytton, Laurence W. also filed stake reports on 28 other companies: Retension Pharmaceuticals, Inc. (Oct 2026), Rank One Computing Corp (Aug 2026), MDxHealth SA (Aug 2026)
Watch TELA Bio, Inc.
Get an email when TELA Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on TELA Bio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on TELA Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on TELA Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Ew Healthcare Partners Fund 2, L.P. | 3,031,617 | 0 | 3,031,617 | 0 | SCHEDULE 13D, 2026-06-09 |
| Ew Healthcare Partners Fund 2-A, L.P. | 4,683,092 | 0 | 4,683,092 | 0 | SCHEDULE 13D, 2026-06-09 |
| EW Healthcare Partners Fund 2-GP, L.P. | 7,714,709 | 0 | 7,714,709 | 0 | SCHEDULE 13D, 2026-06-09 |
| EW Healthcare Partners Fund 2-UGP, LLC | 7,714,709 | 0 | 7,714,709 | 0 | SCHEDULE 13D, 2026-06-09 |
| Nantahala Capital Management, LLC | 0 | 5,794,114 | 0 | 5,794,114 | SCHEDULE 13G/A, 2026-08-14 |
| Wilmot B. Harkey | 0 | 5,794,114 | 0 | 5,794,114 | SCHEDULE 13G/A, 2026-08-14 |
| Daniel Mack | 0 | 5,794,114 | 0 | 5,794,114 | SCHEDULE 13G/A, 2026-08-14 |
| SilverArc Capital Management, LLC | 0 | 2,137,201 | 0 | 2,137,201 | SCHEDULE 13G/A, 2026-08-14 |
| Devesh Gandhi | 0 | 2,137,201 | 0 | 2,137,201 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies TELA Bio, Inc. by CUSIP 872381108 and gives its principal executive office as 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA 19355 (SCHEDULE 13G/A, 2026-08-14).
Source of funds (Item 3)
The funds used to purchase the securities reported herein came from the working capital of EWHP and EWHP-A.Ew Healthcare Partners Fund 2, L.P., SCHEDULE 13D, 2026-06-09
Purpose of Transaction (Item 4)
Ew Healthcare Partners Fund 2, L.P.
The disclosure set forth in Item 6 below is hereby incorporated by reference in this Item 4. This Schedule 13D reports that, on June 9, 2026, an operating partner affiliated with the Reporting Persons was appointed to the Board of Directors of the Issuer. Except as described above, none of the Reporting Persons has any present plan or proposal which relates to, or could result in, any of the events referred to in paragraphs (a) through (j), inclusive, of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-06-09
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Lytton, Laurence W. | 8.5% | SCHEDULE 13G/A |
| 2025-10-15 | Grow Funds, LLC. | SCHEDULE 13G/A | |
| 2025-11-14 | Lytton, Laurence W. | 7.2% | SCHEDULE 13G/A |
| 2025-11-17 | EW Healthcare Partners Fund 2 GP, L.P. | 17.32% | SCHEDULE 13G/A |
| 2026-05-15 | Lytton, Laurence W. | 5.5% | SCHEDULE 13G/A |
| 2026-06-09 | Ew Healthcare Partners Fund 2, L.P. | 17.23% | SCHEDULE 13D |
| 2026-08-11 | SilverArc Capital Management, LLC | 4.8% | SCHEDULE 13G |
| 2026-08-14 | SilverArc Capital Management, LLC | 4.8% | SCHEDULE 13G/A |
| 2026-08-14 | Nantahala Capital Management, LLC | 12.94% | SCHEDULE 13G/A |
Questions about who owns TELA Bio, Inc.
Who owns TELA Bio, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of TELA Bio, Inc.: Ew Healthcare Partners Fund 2, L.P. (17.23%, Schedule 13D, filed 2026-06-09), Nantahala Capital Management, LLC (12.94%, Schedule 13G/A, filed 2026-08-14) and Lytton, Laurence W. (5.5%, Schedule 13G/A, filed 2026-05-15).
Who are the largest shareholders of TELA Bio, Inc.?
By the share each holder's latest filing reports, the largest holders of TELA Bio, Inc. on this page are Ew Healthcare Partners Fund 2, L.P. (17.23%), Nantahala Capital Management, LLC (12.94%) and Lytton, Laurence W. (5.5%).
When did Ew Healthcare Partners Fund 2, L.P. buy into TELA Bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ew Healthcare Partners Fund 2, L.P. on this page is the Schedule 13D, filed 2026-06-09, reporting 17.23%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for TELA Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 31, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| August 4, 2026 | Leadership change: Antony Koblish departs, Director | — | Leadership changes | Source |
| April 30, 2026 | Leadership change: Guido Neels appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for TELA Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.